GSK Explores Potential Link Between Shingles Vaccine and Dementia Risk Reduction

In a groundbreaking development, pharmaceutical giant GSK is investigating whether its highly successful shingles vaccine may also play a significant role in reducing the risk of dementia. This initiative could not only bolster the vaccine’s appeal but also provide new insights into the prevention of neurodegenerative diseases as the global population ages.

Continue reading

EU Reverses Course, Approves Eisai's Alzheimer's Drug After Earlier Rejection

In a significant shift in regulatory stance, the European Union has granted approval to Eisai Co.'s Alzheimer's treatment, marking a notable turnaround from its earlier decision to reject the drug. This development stands to impact the treatment landscape for Alzheimer’s disease and offers renewed hope for patients suffering from this debilitating condition.

Continue reading